Protara Therapeutics (TARA) Profit After Tax (2013 - 2026)

Protara Therapeutics' Profit After Tax history runs 14 years deep, the most recent figure standing at -$17.8 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 49.25% year-over-year to -$17.8 million; the TTM figure through Mar 2026 stood at -$63.3 million (down 39.4% YoY), while the FY2025 annual figure was -$57.4 million, down 28.8% from the prior year.
• Profit After Tax was -$17.8 million for Q1 2026 at Protara Therapeutics, down from -$17.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$7.7 million in Q3 2022 to a low of -$39.0 million in Q4 2022.
• Historically, Profit After Tax has averaged -$13.3 million across 5 years, with a median of -$11.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax tumbled 280.98% in 2022, then surged 73.77% in 2023.
• A 5-year view of Profit After Tax shows it stood at -$39.0 million in 2022, then soared by 73.77% to -$10.2 million in 2023, then fell by 24.93% to -$12.8 million in 2024, then sank by 35.54% to -$17.3 million in 2025, then decreased by 2.74% to -$17.8 million in 2026.
• The last three Profit After Tax figures came in at -$17.8 million (Q1 2026), -$17.3 million (Q4 2025), and -$13.3 million (Q3 2025), per Business Quant data.